"10.1371_journal.pone.0120295","plos one","2015-03-26T00:00:00Z","Marek M Nagiec; Adam P Skepner; Joseph Negri; Michelle Eichhorn; Nicolas Kuperwasser; Eamon Comer; Giovanni Muncipinto; Aravind Subramanian; Clary Clish; Kiran Musunuru; Jeremy R Duvall; Michael Foley; Jose R Perez; Michelle A J Palmer","Therapeutics Platform, Center for the Science of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Metabolite Profiling Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: MMN APS JN AS CC KM JRD MF JRP MAP. Performed the experiments: MMN APS JN ME NK EC GM. Analyzed the data: MMN APS JN ME NK AS CC KM JRD MF JRP MAP. Contributed reagents/materials/analysis tools: EC GM AS. Wrote the paper: MMN APS JN ME NK EC GM AS CC KM JRD MF JRP MAP.","The authors have read the journals policy and have the following competing interests: MMN, JRP, MAP, JRD, APS and EC are inventors on the patent application WO2014028946A2 that includes BRD0418. Patent ownership is assigned to The Broad Institute. BRD0418 is not associated with any commercial entity. Otherwise the authors have declared that no competing interests exist. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2015","03","Marek M Nagiec","MMN",14,FALSE,10,7,12,14,TRUE,TRUE,FALSE,0,NA,FALSE
